TRASYLOL
LOE ApproachingBLAINJECTIONINJECTABLEPriority Review
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRASYLOL is a biological injectable approved in 1993 for an undisclosed indication(s); its mechanism of action and pharmacologic class are not specified in available data. As a biologics license application (BLA) product, it represents an established therapeutic intervention now approaching loss of exclusivity.
LOE Approaching
Moderate competitive pressure (30/100) and approaching LOE suggest a brand defending market share with a contracting team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Aprotinin US Special Access Protocol
Postoperative Hemorrhage
Career Relevance
Zero linked jobs suggest limited active hiring for TRASYLOL roles, reflecting its LOE-approaching status and market maturity. Opportunities are concentrated in defensive commercialization, market access, and transition planning rather than growth initiatives.
Brand Manager
Worked on TRASYLOL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.